Loading…
Loading…
Medicare Part B premiums keep climbing, and Social Security checks keep shrinking to cover them. Three Dividend Kings with very different yields and coverage profiles could shift that math entirely in a retiree's favor.
First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders New SPRAVATO ® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions TITUSVILLE, N.J., Sept. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA).
JEPI's monthly paycheck looks irresistible until you see exactly what the fund surrenders to produce it. Three Dividend Kings quietly sidestep that tradeoff, and the difference compounds in ways most income investors never stop to calculate.
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.
Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in how investors define defensive in the first place.
EFG International AG decreased its position in shares of Johnson and Johnson (NYSE: JNJ) by 5.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 374,628 shares of the company's stock after selling 22,008 shares during the period. Johnson and Johnson
Blue Edge Capital LLC cut its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 18.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,069 shares of the company's stock after selling 3,464 shares during the quarter. Blue Edge Capital LLC's
Corient Private Wealth LP lifted its stake in shares of Johnson and Johnson (NYSE: JNJ) by 127.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,060,922 shares of the company's stock after purchasing an additional 3,393,981 shares during the